Compare Dell Technologies Inc (DELL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Dell Technologies Inc trades at $585.88 (market cap $365.31B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Dell Technologies Inc is far larger — about 21.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DELL | ZBH | |
|---|---|---|
Market Cap | $365.31B | $16.95B |
Volume | 5,121,365 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $588.67 | $103.98 |
52-Week Low | $111.10 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | $388.20B | $24.02B |
Dividend Yield | 0.44% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $586.28, up 1.26% today, with a bullish technical outlook as the price hovers near resistance at $585. Recent earnings beats, including Q2 2026 EPS of $7.04 versus $4.91 expected, and a raised AI server revenue forecast to $74 billion for fiscal 2027 highlight strong operational momentum. The stock's valuation reflects growth expectations with a P/E of 33.42 and P/S of 2.52.
The outlook remains positive driven by AI server demand, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is bullish with a $566.35 price target, though the current price exceeds this, suggesting near-term consolidation may precede further gains if execution continues.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
